275 related articles for article (PubMed ID: 35735209)
1. Seizure underreporting in LGI1 and CASPR2 antibody encephalitis.
Baumgartner T; Pitsch J; Olaciregui-Dague K; Hoppe C; Racz A; Rüber T; Becker A; von Wrede R; Surges R
Epilepsia; 2022 Sep; 63(9):e100-e105. PubMed ID: 35735209
[TBL] [Abstract][Full Text] [Related]
2. Clinical features of 28 cases of anti
Feng J; Li J; Xie Y; Lü Y; Bi F; Zhou J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):386-396. PubMed ID: 37164922
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and long-term outcomes of seizures associated with autoimmune encephalitis: A follow-up study in East China.
Yao L; Yue W; Xunyi W; Jianhong W; Guoxing Z; Zhen H
J Clin Neurosci; 2019 Oct; 68():73-79. PubMed ID: 31331752
[TBL] [Abstract][Full Text] [Related]
4. Anti-LGI1, anti-GABABR, and Anti-CASPR2 encephalitides in Asia: A systematic review.
Ghimire P; Khanal UP; Gajurel BP; Karn R; Rajbhandari R; Paudel S; Gautam N; Ojha R
Brain Behav; 2020 Oct; 10(10):e01793. PubMed ID: 32783406
[TBL] [Abstract][Full Text] [Related]
5. Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis.
Gövert F; Abrante L; Becktepe J; Balint B; Ganos C; Hofstadt-van Oy U; Krogias C; Varley J; Irani SR; Paneva S; Titulaer MJ; de Vries JM; Boon AJW; Schreurs MWJ; Joubert B; Honnorat J; Vogrig A; Ariño H; Sabater L; Dalmau J; Scotton S; Jacob S; Melzer N; Bien CG; Geis C; Lewerenz J; Prüss H; Wandinger KP; Deuschl G; Leypoldt F
Brain; 2023 Feb; 146(2):657-667. PubMed ID: 35875984
[TBL] [Abstract][Full Text] [Related]
6. Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis.
Li TR; Zhang YD; Wang Q; Shao XQ; Lv RJ
CNS Neurosci Ther; 2021 Oct; 27(10):1173-1181. PubMed ID: 34291554
[TBL] [Abstract][Full Text] [Related]
7. Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.
Murayama A; Sugaya K; Hara M; Kawazoe T; Tobisawa S; Nakajima H; Takahashi K
Intern Med; 2023 Jun; 62(11):1659-1663. PubMed ID: 36223927
[TBL] [Abstract][Full Text] [Related]
8. Long-term evolution and prognostic factors of epilepsy in limbic encephalitis with LGI1 antibodies.
Guery D; Cousyn L; Navarro V; Picard G; Rogemond V; Bani-Sadr A; Shor N; Joubert B; Muñiz-Castrillo S; Honnorat J; Rheims S
J Neurol; 2022 Sep; 269(9):5061-5069. PubMed ID: 35595970
[TBL] [Abstract][Full Text] [Related]
9. Contemporary advances in antibody-mediated encephalitis: anti-LGI1 and anti-Caspr2 antibody (Ab)-mediated encephalitides.
Seery N; Butzkueven H; O'Brien TJ; Monif M
Autoimmun Rev; 2022 May; 21(5):103074. PubMed ID: 35247644
[TBL] [Abstract][Full Text] [Related]
10. Antibody induced seizure susceptibility and impaired cognitive performance in a passive transfer rat model of autoimmune encephalitis.
Pişkin ŞA; Korkmaz HY; Ulusoy CA; Şanlı E; Küçükali CI; Onat F; Tüzün E; Çarçak N
Front Immunol; 2023; 14():1268986. PubMed ID: 38035091
[TBL] [Abstract][Full Text] [Related]
11. Long-term seizure outcomes in patients with autoimmune encephalitis: A prospective observational registry study update.
Liu X; Guo K; Lin J; Gong X; Li A; Zhou D; Hong Z
Epilepsia; 2022 Jul; 63(7):1812-1821. PubMed ID: 35357695
[TBL] [Abstract][Full Text] [Related]
12. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABA
Shen CH; Fang GL; Yang F; Cai MT; Zheng Y; Fang W; Guo Y; Zhang YX; Ding MP
Ann Clin Transl Neurol; 2020 Aug; 7(8):1392-1399. PubMed ID: 32710704
[TBL] [Abstract][Full Text] [Related]
13. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
Dubey D; Britton J; McKeon A; Gadoth A; Zekeridou A; Lopez Chiriboga SA; Devine M; Cerhan JH; Dunlay K; Sagen J; Ramberger M; Waters P; Irani SR; Pittock SJ
Ann Neurol; 2020 Feb; 87(2):313-323. PubMed ID: 31782181
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
16. Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABA
Cui D; Feng J; Yang M; Dong Y; Lian Y
Neurol Sci; 2024 Apr; 45(4):1609-1617. PubMed ID: 37940748
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1/Caspr2 encephalitis: a prospective cohort study in Western China.
Guo K; Liu X; Lin J; Gong X; Li A; Liu Y; Zhou D; Hong Z
Ther Adv Neurol Disord; 2022; 15():17562864211073203. PubMed ID: 35069805
[TBL] [Abstract][Full Text] [Related]
18. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
Michael S; Waters P; Irani SR
Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
[TBL] [Abstract][Full Text] [Related]
19. LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome.
Nosadini M; Toldo I; Tascini B; Bien CG; Parmeggiani L; De Gaspari P; Zuliani L; Sartori S
J Neuroimmunol; 2019 Oct; 335():577008. PubMed ID: 31352183
[TBL] [Abstract][Full Text] [Related]
20. Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis.
Smith KM; Dubey D; Liebo GB; Flanagan EP; Britton JW
Neurology; 2021 Sep; 97(11):e1141-e1149. PubMed ID: 34233939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
